Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes
Presenter: Rowan Howell
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Comprehensive analysis of clinical characteristics and germline status among colorectal cancer patients in a tertiary care center in Thailand
Presenter: NUTDANAI ROILA
Session: Cocktail & Poster Display session
Resources:
Abstract